Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Diamedica Therapeutics Inc
(NQ:
DMAC
)
2.440
+0.060 (+2.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 27, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
9,708
Open
2.370
Bid (Size)
2.320 (8)
Ask (Size)
2.460 (4)
Prev. Close
2.380
Today's Range
2.350 - 2.460
52wk Range
2.120 - 9.550
Shares Outstanding
26,443,067
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022
May 25, 2022
From
DiaMedica Therapeutics
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results
May 04, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Performance
YTD
-37.11%
-37.11%
1 Month
+7.02%
+7.02%
3 Month
-7.22%
-7.22%
6 Month
-32.78%
-32.78%
1 Year
-67.07%
-67.07%
More News
Read More
Earnings Preview For DiaMedica Therapeutics
May 03, 2022
Via
Benzinga
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022
April 28, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results
March 14, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Earnings Scheduled For March 14, 2022
March 14, 2022
Via
Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Via
Benzinga
DiaMedica Therapeutics Earnings Preview
March 11, 2022
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Via
Benzinga
DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer
February 02, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Present Research at International Stroke Conference
January 25, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
January 05, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event
December 13, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 17, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results
November 10, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021
November 09, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial
November 08, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021
November 04, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021
October 18, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Via
Benzinga
Exposures
COVID-19
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke
September 30, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Via
Benzinga
DiaMedica Therapeutics Announces Closing of $30 Million Private Placement
September 28, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
50 Biggest Movers From Yesterday
September 28, 2021
Via
Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; ASLAN Pharmaceuticals Shares Slide
September 27, 2021
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.